Abstract

Dyslipidaemia is an important risk factor in the development of atherosclerotic cardiovascular disease in people with diabetes. This article discusses the lipid modifying therapies available, and the current evidence and guidance on their use in diabetes.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call